<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">


Press Releases

Our latest announcements

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

Biodesix presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules.

Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors

Biodesix, Inc. is proud to announce that its CFO, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors.

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

Biodesix announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.

Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

Biodesix announces its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.

Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference

Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person investor meetings at Cowen’s 43rd Annual Healthcare Conference.

Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update.

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test

announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York

Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

Biodesix announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors effective January 3, 2023.

Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine

Biodesix named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine issue, Top 10 Proteomics Solutions Companies of 2022.

Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

Biodesix announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.

1 2 3 4 5 6 7 8 9 Last